

NEW TEST: GNR AST
NOTIFICATION DATE: 7/21/2025
EFFECTIVE DATE: 7/28/2025

New Test Name- VITEK® 2 AST-N807

EXPLANATION: Our susceptibility card for select gram-negative bacilli has been discontinued. A multi-phase implementation approach will be taken as verification studies are performed to bring up testing of new cards. The following drugs will be reported in the first phase starting on July 28, 2025. This new susceptibility card will be for select gram-negative bacilli (Enterobacterales, *Pseudomonas aeruginosa*). Testing for other non-fermenters and Acinetobacter species will be unaffected by this change. Not all antibiotics will be released for all organisms. Card limitations, characteristics of the organism, and antibiotic stewardship considerations will determine which drugs will be released.

AMPICILLIN

CEFAZOLIN

CEFEPIME

CEFOXITIN

CEFTAZIDIME

CEFTRIAXONE

CIPROFLOXACIN

ERTAPENEM

GENTAMICIN

LEVOFLOXACIN

MEROPENEM

NITROFURATOIN

PIP/TAZO

SXT

AMP/SUL

QUESTIONS ABOUT THIS TESTING

Amanda Murray, Laboratory Supervisor, Microbiology, 304-598-4235 (amanda.murray@wvumedicine.org)
Elizabeth Thorne, Laboratory Supervisor, Microbiology, 304-598-4235 (elizabeth.thorne@wvumedicine.org)
Ryan Demkowicz, Medical Director, Microbiology, 304-598-4000 ext. 72740 (ryan.demkowicz@hsc.wvu.edu)

Contact WVUH Laboratories or UML Representatives

304-598-4225